Why did Tesla shares plunge after Musk’s political move?
What’s driving CoreWeave’s $9B acquisition of Core Scientific?
How will Trump’s 25% tariffs impact US trade?
Why is Apple appealing the EU’s $580M fine?
What caused McDonald’s recent major announcement?
How are Texas floods affecting local businesses?
Why is Nvidia’s stock surging in 2025?
KalVista Ends Its Unexpectedly Messy Path To Approval In HAE Treatment
investors.com/news/technology/kalvista-pharmaceuticals-fda-approval-ekterly
The FDA signed off on KalVista Pharmaceuticals' emergency treatment for swelling attacks associated with a rare, genetic disease.
The post KalVista Ends Its Unexpectedly Messy Path To Approval In HAE Treatment appeared first on Investor's Business Daily.
This story appeared on investors.com, 2025-07-07 13:12:40.